Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non-Inferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission.
Joanna KedraPhilippe DieudéCaroline GiboinHubert MarotteCarine SalliotThierry SchaeverbekeAleth PerdrigerMartin SoubrierJacques MorelArnaud ConstantinEmmanuelle DernisValérie RoyantJean-Hugues SalmonThao PhamJacques-Eric GottenbergEdouard PertuisetMaxime DougadosValérie Devauchelle-PensecPhilippe GaudinGrégoire CormierPhilippe GoupilleXavier MarietteFrancis BerenbaumDidier AlcaixSid-Ahmed RouidiJean-Marie BerthelotAgnès MonnierChristine PirothFrédéric LiotéVincent GoëbCécile Gaujoux-VialaIsabelle Chary-ValckenaereDavid HajageFlorence TubachBruno Fautrelnull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
The ToLEDo trial failed to demonstrate NI for the proposed ABA or TCZ tapering strategy.
Keyphrases
- rheumatoid arthritis
- open label
- phase iii
- disease activity
- phase ii
- double blind
- study protocol
- clinical trial
- rheumatoid arthritis patients
- placebo controlled
- phase ii study
- ankylosing spondylitis
- transcription factor
- juvenile idiopathic arthritis
- interstitial lung disease
- ultrasound guided
- arabidopsis thaliana
- cross sectional
- systemic lupus erythematosus
- metal organic framework
- radiation therapy
- ulcerative colitis
- locally advanced